GlaxoSmithKline plc (GSK)
Pre-market:
| Previous close | 45.12 |
| Open | 44.70 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1300 |
| Day's range | 44.22 - 44.75 |
| 52-week range | 33.33 - 45.93 |
| Volume | |
| Avg. volume | 3,141,429 |
| Market cap | 93.361B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 16.32 |
| EPS (TTM) | 2.71 |
| Earnings date | 31 Jul 2024 |
| Forward dividend & yield | 1.50 (3.33%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | 46.39 |
Fool.co.ukThese FTSE 100 shares could rise 15% to 36% in the next year!
Is the market underestimating these top FTSE 100 stocks? Royston Wild explains why analysts expect these two blue-chip shares to rocket in value. The post These FTSE 100 shares could rise 15% to 36% in the next year! appeared first on The Motley Fool UK.
BenzingaZantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
A Chicago jury rejected an Illinois woman’s claim that the discontinued heartburn drug Zantac caused her colon cancer. This case is the first of thousands of similar lawsuits. The jury in Cook County, Illinois, found that Angela Valadez, an 89-year-old Illinois resident, did not prove her cancer was linked to her Zantac use. Related: GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims. Valadez alleged that her cancer resulted from taking over-the-
Fool.co.ukUK stocks are hitting all-time highs! Yet these 2 still look cheap to me
The FTSE 100's on a roll. But it's still possible to pick bargain UK stocks, provided we know where to look, says Harvey Jones The post UK stocks are hitting all-time highs! Yet these 2 still look cheap to me appeared first on The Motley Fool UK.
